Table 2. Univariate and multivariate survival analysis in 43 dialysis and 129 non-dialysis age, sex matched control patients.
| Overall survival | Number | Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|---|
| 1-year survival (%) | 3-year survival (%) | P | HR | 95% CI | P | |||
| Age (≤60/>60 years) | 80/92 | 71/53 | 59/41 | 0.803 | ||||
| Sex (male/female) | 112/60 | 62/69 | 45/48 | 0.292 | ||||
| HBsAg (negative/positive) | 83/89 | 62/67 | 39/53 | 0.141 | ||||
| Anti-HCV (negative/positive) | 109/63 | 62/70 | 48/44 | 0.513 | ||||
| Albumin level (≥3.5/<3.5 g/dL) | 104/68 | 79/42 | 64/20 | <0.001 | ||||
| Bilirubin level (≤1.1/>1.1 mg/dL) | 121/51 | 71/49 | 51/34 | 0.027 | ||||
| ALT (≤40/>40 IU/L) | 77/95 | 70/61 | 53/41 | 0.005 | ||||
| Platelet (≥150,000/<150,000/μL) | 79/93 | 58/70 | 42/50 | 0.366 | ||||
| INR of PT (≤1.1/>1.1) | 109/63 | 72/52 | 55/30 | <0.001 | ||||
| AFP (≤20/>20 ng/mL) | 72/100 | 73/58 | 59/37 | 0.005 | ||||
| TTV (≤33/>33 cm3) | 80/92 | 82/49 | 69/26 | <0.001 | 1.852 | 1.201–2.856 | 0.005 | |
| Vascular invasion (no/yes) | 135/37 | 73/34 | 55/15 | <0.001 | ||||
| Distant metastasis (no/yes) | 161/11 | 68/11 | 49/0 | <0.001 | 2.673 | 1.320–5.412 | 0.006 | |
| Ascites (no/yes) | 123/49 | 75/38 | 57/21 | <0.001 | 1.608 | 1.061–2.439 | 0.025 | |
| Dialysis (no/yes) | 129/43 | 68/55 | 55/33 | 0.005 | 1.713 | 1.140–2.573 | 0.010 | |
| Performance status | ||||||||
| 0 | 103 | 77 | 63 | |||||
| 1 | 53 | 49 | 26 | <0.001 | ||||
| 2–4 | 16 | 38 | 13 | <0.001 | ||||
| ALBI grade | ||||||||
| Grade 1 | 72 | 86 | 75 | 1 | ||||
| Grade 2 | 81 | 53 | 29 | <0.001 | 2.077 | 1.362–3.168 | 0.001 | |
| Grade 3 | 19 | 37 | 13 | <0.001 | 2.371 | 1.235–4.550 | 0.009 | |
| Curative/noncurative treatments, n (%) | 70/102 | 91/47 | 75/27 | <0.001 | 2.263 | 1.449–3.535 | <0.001 | |
The forepart of the parentheses was set as the reference group in the univariate and multivariate analysis. AFP, ɑ-fetoprotein; ALBI, albumin-bilirubin; ALT, alanine aminotransferase; anti-HCV, antibody against hepatitis C virus; HBsAg, hepatitis B virus surface antigen; INR of PT, international normalized ratio of prothrombin time.